The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology
Open accessAbstract
OBJECTIVE: Research and clinical translation in schizophrenia is limited by inconsistent definitions of treatment resistance and response. To address this issue, the authors evaluated current approaches and then developed consensus criteria and guidelines. METHOD: A systematic review of randomized antipsychotic clinical trials in treatment-resistant schizophrenia was performed, and definitions of treatment resistance were extracted. Subsequently, consensus operationalized criteria were developed through 1) a multiphase, mixed methods approach, 2) identification of key criteria via an online survey, and 3) meetings to achieve consensus. RESULTS: Of 2,808 studies identified, 42 met inclusion criteria. Of these, 21 studies (50%) did not provide operationalized criteria. In the remaining studies, criteria varied considerably, particularly regarding symptom severity, prior treatment duration, and antipsychotic dosage thresholds; only two studies (5%) utilized the same criteria. The consensus group identified minimum and optimal criteria, employing the following principles: 1) current symptoms of a minimum duration and severity determined by a standardized rating scale; 2) moderate or worse functional impairment; 3) prior treatment consisting of at least two different antipsychotic trials, each for a minimum duration and dosage; 4) systematic monitoring of adherence and meeting of minimum adherence criteria; 5) ideally at least one prospective treatment trial; and 6) criteria that clearly separate responsive from treatment-resistant patients. CONCLUSIONS: There is considerable variation in current approaches to defining treatment resistance in schizophrenia. The authors present consensus guidelines that operationalize criteria for determining and reporting treatment resistance, adequate treatment, and treatment response, providing a benchmark for research and clinical translation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
(1976) · Medical Entomology and Zoology · Cited by 8,899
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Self-citationLeucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Scale for the Assessment of Negative Symptoms
Andreasen, N. C. (2014) · PsycTESTS Dataset · doi:10.1037/t12696-000 · Cited by 1,866
Keefe, R. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2003.09.011 · Cited by 1,573
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
International Consensus Study of Antipsychotic Dosing
Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09060802 · Cited by 1,301
Morosini, P. L., Magliano, L., Brambilla, L., Ugolini, S., & Pioli, R. (2000) · PubMed · Cited by 1,168
McGorry, P. D., Yung, A. R., Phillips, L. J., Yuen, H. P., Francey, S., Cosgrave, E. M., Germano, D., Bravin, J., McDonald, T., Blair, A., et al. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.10.921 · Cited by 1,056
Jones, S. H., Thornicroft, G., Coffey, M., & Dunn, G. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.166.5.654 · Cited by 1,015
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011
Hiemke, C., Baumann, P., Bergemann, N., Conca, A., Dietmaier, O., Egberts, K., Fric, M., Gerlach, M., Greiner, C., Gründer, G., et al. (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1286287 · Cited by 868
Schizophrenia: an integrated sociodevelopmental-cognitive model
Howes, O. D., & Murray, R. M. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62036-x · Cited by 864
Self-citationPractice Guideline for the Treatment of Patients With Schizophrenia Second Edition
(2007) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.45859 · Cited by 737
Haro, J. M., Kamath, S. A., Ochoa, S., Novick, D., Rele, K., Fargas, A., Rodríguez, M. J., Rele, R., Orta, J., Kharbeng, A., et al. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.107.s416.5.x · Cited by 656
Natural Course of Schizophrenic Disorders: A 15-Year Followup of a Dutch Incidence Cohort
Wiersma, D., Nienhuis, F. J., Slooff, C. J., & Giel, R. (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033315 · Cited by 649
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Self-citationKane, J. M., Kishimoto, T., & Correll, C. U. (2013) · World Psychiatry · doi:10.1002/wps.20060 · Cited by 520
Self-citationScale for the Assessment of Positive Symptoms
Andreasen, N. C. (2018) · PsycTESTS Dataset · doi:10.1037/t48377-000 · Cited by 502
Leucht, S., Komossa, K., Rummel-Kluge, C., Corves, C., Hunger, H., Schmid, F., Asenjo Lobos, C., Schwarz, S., & Davis, J. M. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030368 · Cited by 490
Royal Australian And New Zealand College Of Psychiatrists Clinical Practice Guidelines Team For The Treatment Of Schizophrenia And Related Disorders (2005) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2005.01516.x · Cited by 435
Delayed-Onset Hypothesis of Antipsychotic Action: A Hypothesis Tested and Rejected
Agid, O., Kapur, S., Arenovich, T., & Zipursky, R. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.12.1228 · Cited by 408
Self-citation(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.12.1744 · Cited by 382
Dose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method
Leucht, S., Samara, M., Heres, S., Patel, M. X., Woods, S. W., & Davis, J. M. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu001 · Cited by 372
Barnes, T. R., & the Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 356
History of the Discovery and Clinical Introduction of Chlorpromazine
López-Muñoz, F., Alamo, C., cuenca, E., Shen, W., Clervoy, P., & Rubio, G. (2005) · Annals of Clinical Psychiatry · doi:10.1080/10401230591002002 · Cited by 354
Howes, O. D., Vergunst, F., Gee, S., McGuire, P., Kapur, S., & Taylor, D. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.105833 · Cited by 353
Self-citationLieberman, J. A., Phillips, M., Gu, H., Stroup, S., Zhang, P., Kong, L., Ji, Z., Koch, G., & Hamer, R. M. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300157 · Cited by 345
Demjaha, A., Egerton, A., Murray, R. M., Kapur, S., Howes, O. D., Stone, J. M., & McGuire, P. K. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.06.011 · Cited by 342
Self-citationZhang, J.-P., Gallego, J. A., Robinson, D. G., Malhotra, A. K., Kane, J. M., & Correll, C. U. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001277 · Cited by 336
Self-citationHuhn, M., Tardy, M., Spineli, L. M., Kissling, W., Förstl, H., Pitschel-Walz, G., Leucht, C., Samara, M., Dold, M., Davis, J. M., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.112 · Cited by 333
Linking the PANSS, BPRS, and CGI: Clinical Implications
Leucht, S., Kane, J. M., Etschel, E., Kissling, W., Hamann, J., & Engel, R. R. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301147 · Cited by 333
Self-citationFalkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., WFSBP Task Force on Treatment Guide, Falkai, P., Wobrock, T., Lieberman, J., et al. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970500483177 · Cited by 331
Self-citationClozapine versus typical neuroleptic medication for schizophrenia
Essali, A., Al-Haj Haasan, N., Li, C., & Rathbone, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000059.pub2 · Cited by 329
Dopamine Synthesis Capacity in Patients With Treatment-Resistant Schizophrenia
Demjaha, A., Murray, R. M., McGuire, P. K., Kapur, S., & Howes, O. D. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12010144 · Cited by 325
Self-citationDose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose Method
Leucht, S., Samara, M., Heres, S., Patel, M. X., Furukawa, T., Cipriani, A., Geddes, J., & Davis, J. M. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv037 · Cited by 318
Assessing levels of adaptive functioning: The Role Functioning Scale
Goodman, S. H., Sewell, D. R., Cooley, E. L., & Leavitt, N. (1993) · Community Mental Health Journal · doi:10.1007/bf00756338 · Cited by 307
The Risks and Benefits of Clozapine versus Chlorpromazine
CLAGHORN, J., HONIGFELD, G., ABUZZAHAB, F. S., WANG, R., STEINBOOK, R., TUASON, V., & KLERMAN, G. (1987) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198712000-00002 · Cited by 301
Samara, M. T., Dold, M., Gianatsi, M., Nikolakopoulou, A., Helfer, B., Salanti, G., & Leucht, S. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2955 · Cited by 300
The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal
Brissos, S., Veguilla, M. R., Taylor, D., & Balanzá-Martinez, V. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314540297 · Cited by 297
Self-citationSommer, I. E., Daalman, K., Rietkerk, T., Diederen, K. M., Bakker, S., Wijkstra, J., & Boks, M. P. M. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn130 · Cited by 282
Self-citationMeltzer, H. Y., Bastani, B., Kwon, K. Y., Ramirez, L. F., Burnett, S., & Sharpe, J. (1989) · Psychopharmacology · doi:10.1007/bf00442563 · Cited by 271
Self-citationFalkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., WFSBP Task Force on Treatment Guidelines for Schizophrenia, Falkai, P., Wobrock, T., Lieberman, J., et al. (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510030090 · Cited by 269
Self-citationSchulte, P. F. J. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00001 · Cited by 264
BELL, M., MILSTEIN, R., BEAM-GOULET, J., LYSAKER, P., & CICCHETTI, D. (1992) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199211000-00007 · Cited by 261
Pharmacokinetics and Pharmacodynamics of Clozapine
Jann, M. W., Grimsley, S. R., Gray, E. C., & Chang, W.-H. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324020-00005 · Cited by 257
A systematic review of the evidence of clozapine's anti-aggressive effects
Frogley, C., Taylor, D., Dickens, G., & Picchioni, M. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114571100201x · Cited by 252
Self-citationRelationships Among Subjective and Objective Measures of Adherence to Oral Antipsychotic Medications
Velligan, D. I., Wang, M., Diamond, P., Glahn, D. C., Castillo, D., Bendle, S., Lam, Y. W. F., Ereshefsky, L., & Miller, A. L. (2007) · Psychiatric Services · doi:10.1176/appi.ps.58.9.1187 · Cited by 249
At Issue: Defining Treatment Refractoriness in Schizophrenia
Brenner, H. D., Dencker, S. J., Goldstein, M. J., Hubbard, J. W., Keegan, D. L., Kruger, G., Kulhanek, F., Liberman, R. P., Malm, U., & Midha, K. K. (1990) · Schizophrenia Bulletin · doi:10.1093/schbul/16.4.551 · Cited by 242
Howes, O., Egerton, A., Allan, V., McGuire, P., Stokes, P., & Kapur, S. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788957528 · Cited by 239
Self-citationPast and Present Progress in the Pharmacologic Treatment of Schizophrenia
Kane, J. M., & Correll, C. U. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10r06264yel · Cited by 232
Self-citationAgid, O., Arenovich, T., Sajeev, G., Zipursky, R. B., Kapur, S., Foussias, G., & Remington, G. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05785yel · Cited by 224
Self-citationHowes, O. D., & Kapur, S. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.113.138578 · Cited by 203
Self-citationKolakowska, T., Williams, A. O., Ardern, M., Reveley, M. A., Jambor, K., Gelder, M. G., & Mandelbrote, B. M. (1985) · British Journal of Psychiatry · doi:10.1192/bjp.146.3.229 · Cited by 194
Suzuki, T., Remington, G., Mulsant, B. H., Uchida, H., Rajji, T. K., Graff-Guerrero, A., Mimura, M., & Mamo, D. C. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.02.013 · Cited by 176
Self-citationLeucht, S. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13049su1c.02 · Cited by 174
Computerized assessment of cognition in schizophrenia: Promises and pitfalls of CANTAB
Levaux, M.-N., Potvin, S., Sepehry, A. A., Sablier, J., Mendrek, A., & Stip, E. (2007) · European Psychiatry · doi:10.1016/j.eurpsy.2006.11.004 · Cited by 174
Modeling the Early Course of Schizophrenia
Hafner, H., Maurer, K., Loffler, W., der Heiden, W. A., Hambrecht, M., & Schultze-Lutter, F. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007008 · Cited by 167
Time Course for Antipsychotic Treatment Response in First-Episode Schizophrenia
Emsley, R., Rabinowitz, J., & Medori, R. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.743 · Cited by 162
Besch, C. L. (1995) · AIDS · doi:10.1097/00002030-199501000-00001 · Cited by 148
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia
Bitter, I., Dossenbach, M. R. K., Brook, S., Feldman, P. D., Metcalfe, S., Gagiano, C. A., Füredi, J., Bartkó, G., Janka, Z., Bánki, C. M., et al. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.033 · Cited by 147
The natural history and pathophysiology of treatment resistant schizophrenia
Sheitman, B. B., & Lieberman, J. A. (1998) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(97)00052-6 · Cited by 140
Jónsdóttir, H., Opjordsmoen, S., Birkenaes, A. B., Engh, J. A., Ringen, P. A., Vaskinn, A., Aamo, T. O., Friis, S., & Andreassen, O. A. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181d2191e · Cited by 132
Lenior, M. E., Dingemans, P. M. A. J., LINSZEN, D. H., de Haan, L., & Schene, A. H. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.179.1.53 · Cited by 129
Treatment resistant schizophrenia and response to antipsychotics: A review
Suzuki, T., Remington, G. J., Mulsant, B. H., Rajji, T. K., Uchida, H., Graff‐Guerrero, A., & Mamo, D. C. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.09.016 · Cited by 121
Self-citationQuantifying Clinical Relevance in the Treatment of Schizophrenia
Correll, C. U., Kishimoto, T., Nielsen, J., & Kane, J. M. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.11.016 · Cited by 113
Self-citationTreatment response after relapse in a placebo-controlled maintenance trial in schizophrenia
Emsley, R., Nuamah, I., Hough, D., & Gopal, S. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.02.030 · Cited by 110
Time to clozapine response in a standardized trial
Conley, R. R., Carpenter, W. T., & Tamminga, C. A. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.9.1243 · Cited by 106
Self-citationClozapine Treatment of Outpatients With Schizophrenia: Outcome and Long-Term Response Patterns
Breier, A. F., Buchanan, R. W., Irish, D., & Carpenter, W. T. (2000) · Psychiatric Services · doi:10.1176/appi.ps.51.10.1249 · Cited by 104
Self-citationClozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?
Remington, G. J., Agid, O., Foussias, G., Ferguson, L., McDonald, K., & Powell, V. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2922-7 · Cited by 99
Self-citationThe Role of Clozapine in Treatment-Resistant Schizophrenia
Kane, J. M., & Correll, C. U. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2966 · Cited by 98
Self-citationHowes, O. D., Shotbolt, P., Bloomfield, M., Daalman, K., Demjaha, A., Diederen, K. M. J., Ibrahim, K., Kim, E., McGuire, P. K., Kahn, R. S., et al. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr195 · Cited by 94
Self-citationNew second-generation long-acting injectable antipsychotics for the treatment of schizophrenia
Citrome, L. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.811984 · Cited by 85
Self-citationComparison of Treatment Response in Second-Episode Versus First-Episode Schizophrenia
Emsley, R. A., Oosthuizen, P., Koen, L., Niehaus, D. J. H., & Martínez, L. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31827bfcc1 · Cited by 84
Is the PANSS used correctly? a systematic review
Obermeier, M., Schennach-Wolff, R., Meyer, S., Möller, H., Riedel, M. J., Krause, D., & Seemüller, F. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-113 · Cited by 83
Self-citationClozapine for the treatment of schizophrenia
Fakra, É., & Azorin, J. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.709235 · Cited by 82
Insight in Schizophrenia: A Review
Baier, M. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0125-7 · Cited by 82
Girgis, R. R., Phillips, M. R., Li, X., Li, K., Jiang, H., Wu, C., Duan, N., Niu, Y., & Lieberman, J. A. (2011) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.110.081471 · Cited by 73
McCutcheon, R. A., Beck, K., Bloomfield, M., Marques, T. R., Rogdaki, M., & Howes, O. D. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115576688 · Cited by 63
Self-citationLee, J., Takeuchi, H., Fervaha, G., Sin, G. L., Foussias, G., Agid, O., Farooq, S., & Remington, G. J. (2015) · The Canadian Journal of Psychiatry · doi:10.1177/070674371506001107 · Cited by 60
Self-citationOlanzapine Treatment of Residual Positive and Negative Symptoms
Buchanan, R. W., Ball, M. P., Weiner, E., Kirkpatrick, B. W., Gold, J. M., McMahon, R. P., & Carpenter, W. T. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.124 · Cited by 59
Self-citationPredictors of Clinical Outcome in Schizophrenic Patients Responding to Clozapine
Mauri, M. C., Volonteri, L. S., Dell’Osso, B. M., Regispani, F., Papa, P., Baldi, M., & Bareggi, S. R. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000095351.32154.3a · Cited by 57
Fabrazzo, M. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00319-6 · Cited by 56
The Clinical Use of Plasma Clozapine Levels
Bell, R., McLaren, A., Gaianos, J., & Copolov, D. (1998) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048679809068332 · Cited by 55
Clozapine plasma level monitoring: Current status
Cooper, T. B. (1996) · Psychiatric Quarterly · doi:10.1007/bf02326373 · Cited by 36
Pharmacotherapy for treatment-refractory schizophrenia
Sant, S. V., & Buckley, P. F. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.528200 · Cited by 29
Ministry of Health clinical practice guidelines: schizophrenia.
Verma, S., Chan, L., Chee, K. S., Chen, H., Chin, S., Chong, S. A., Chua, W., Fones, C. S. L., Fung, D. S. S., Khoo, C. L., et al. (2011) · PubMed · Cited by 27
Delayed onset hypothesis of antipsychotic action — a hypothesis tested and rejected
Agid, O., Kapur, S., Arenovich, T., & Zipursky, R. B. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)80242-6 · Cited by 25
Self-citationSherwood, M., Thornton, A. E., & Honer, W. G. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112440513 · Cited by 17
Self-citationLee, J., Takeuchi, H., Fervaha, G., Sin, G. L., Foussias, G., Agid, O., Farooq, S., & Remington, G. J. (2016) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.140306 · Cited by 11
Self-citationOptimising treatment of refractory schizophrenia
Beck, K., & Howes, O. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3076-y · Cited by 3
Self-citation
Cited by
Firth, J., Siddiqi, N., Koyanagi, A., Siskind, D., Rosenbaum, S., Galletly, C., Allan, S., Caneo, C., Carney, R., Carvalho, A. F., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30132-4 · Cited by 1,531
Self-citationDopamine and glutamate in schizophrenia: biology, symptoms and treatment
McCutcheon, R. A., Krystal, J. H., & Howes, O. D. (2020) · World Psychiatry · doi:10.1002/wps.20693 · Cited by 612
Self-citationBarnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Self-citationImproving outcomes of first‐episode psychosis: an overview
Fusar‐Poli, P., McGorry, P. D., & Kane, J. M. (2017) · World Psychiatry · doi:10.1002/wps.20446 · Cited by 575
Self-citationTaipale, H., Tanskanen, A., Mehtälä, J., Vattulainen, P., Correll, C. U., & Tiihonen, J. (2020) · World Psychiatry · doi:10.1002/wps.20699 · Cited by 415
Self-citation
Metadata
- Authors
- Howes, O. D., McCutcheon, R., Agid, O., de Bartolomeis, A., van Beveren, N. J. M., Birnbaum, M. L., Bloomfield, M. A. P., Bressan, R. A., Buchanan, R. W., Carpenter, W. T., Castle, D. J., Citrome, L., Daskalakis, Z. J., Davidson, M., Drake, R. J., Dursun, S., Ebdrup, B. H., Elkis, H., Falkai, P., Fleischacker, W. W., Gadelha, A., Gaughran, F., Glenthøj, B. Y., Graff-Guerrero, A., Hallak, J. E. C., Honer, W. G., Kennedy, J., Kinon, B. J., Lawrie, S. M., Lee, J., Leweke, F. M., MacCabe, J. H., McNabb, C. B., Meltzer, H., Möller, H.-J., Nakajima, S., Pantelis, C., Reis Marques, T., Remington, G., Rossell, S. L., Russell, B. R., Siu, C. O., Suzuki, T., Sommer, I. E., Taylor, D., Thomas, N., Üçok, A., Umbricht, D., Walters, J. T. R., Kane, J., & Correll, C. U.
- Venue
- American Journal of Psychiatry
- Published
- 2017-03
- Volume
- 174
- Issue
- 3
- Pages
- 216-229
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2560754155
- Cited by
- 1,132
- References
- 92
- FWCI
- 53.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.